Articles from LinusBio

LinusBio, a leader in exposomic sequencing and precision health, today launched Traced™ Environmental Exposure Test, a direct-to-consumer wellness product that measures essential, non-essential, and toxic elements in a hair sample over a period of 30 days. Developed from research at Mount Sinai and built on LinusBio's proprietary platform, the test is now available to consumers across the United States (except New York).

LinusBio, a leader in exposomic sequencing and precision health, today announced that ClearStrand™ASD, its first-of-its-kind biochemical test designed to help rule out autism spectrum disorder (ASD), is now available for children up to age 10. This broadens the test’s previously validated use beyond children under 48 months, making it the only objective autism rule-out test that spans from infancy through childhood. The expansion is supported by data from a global study of 1,697 participants, which has been submitted for publication in a peer-reviewed journal.

LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally.

LinusBio, a leader in precision exposome medicine, and Coralis Health, a pioneering virtual care platform for neurodivergent children and families, today announced a partnership to provide comprehensive end-to-end diagnostic services for autism spectrum disorder (ASD). This collaboration combines LinusBio's breakthrough ClearStrand-ASD™ biomarker test with Coralis Health's specialized care platform, creating a seamless pathway from early screening to diagnosis and intervention.

LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in California, making it available across 48 states in the US. This expansion marks a significant step in LinusBio’s mission to enable earlier identification of autism spectrum disorder (ASD) and support early intervention.

LinusBio, a leader in precision exposome medicine, today announced ClearStrand-ASD™, a first-of-its-kind diagnostic aid for autism spectrum disorder (ASD). ClearStrand-ASD is a biochemical test that identifies a molecular signature predictive of autism in a strand of hair. It is designed to help physicians rule out the condition in children between one and 36 months of age when autism is a concern. The test provides a negative predictive value (NPV) of 92.5% and can help providers identify children who are unlikely to be on the autism spectrum. Results may help inform decisions to refer a child for early intervention and for diagnostic evaluation by an autism specialist.

LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list for 2023. This annual special report highlights the most innovative private medtech companies that are making significant strides in the industry.

LinusBio, a leader in precision exposome sequencing, and Y.A.C. Holdings, a Japanese multinational, today announced a partnership with a 1 Billion Yen investment by Y.A.C. in LinusBio. The partnership is part of a series A2 funding round, in which the company raised an additional $8 million, bringing the total funding raised by LinusBio to over $25.5M in the last 18 months.

LinusBio, a leader in precision exposome sequencing, today announced it raised over $16 million in Series A funding to deliver a novel platform that bridges genomics, the environment, and biological response.